Expanding Treatment Options to Address Unmet Need in Blood Cancer

Every three minutes, someone in the United States is diagnosed with a type of blood cancer. Blood cancers affect the production and function of blood cells and typically begins in bone marrow, where blood is produced. When blood cells become cancerous, uncontrolled growth of abnormal blood cells interrupts the normal development process and prevents blood cells from performing their vital functions, like fighting off infections or preventing serious bleeding.

Today, 1.3 million people in the U.S. are living with or are in remission from blood cancers. In 2017, troubling statistics show that blood cancers are expected to take the lives of more than 58,000 Americans. 


For the millions of patients and their families impacted by blood cancers, recent scientific advances have resulted in a deeper understanding of blood cancers, leading to new treatments and improved outcomes. We are dedicated to further accelerate this momentum through scientific discovery and collaboration to one day eliminate cancer as a cause of death.

Hematology is one of four key oncology disease areas of focus at AstraZeneca. Our diverse hematology pipeline aims to deliver highly effective and well tolerated therapies for a range of blood cancers, with more than 35 clinical trials underway addressing more than 10 blood cancer types in both monotherapy and combination therapies. 



Investments and collaborations with like-minded science-led companies help our researchers push the boundaries of what’s possible in cancer care, and are a central component of our approach in hematology. Our investment in Acerta Pharma, AstraZeneca’s hematology research and development center of excellence, is a primary example of this commitment. We believe focused collaborations such as this, which leverage complementary resources, will result in the delivery of life-changing medicines to the patients battling blood cancers.

As we embark on our ambitious journey in hematology, we commit to working with urgency, precision and passion to rapidly advance our scientific discovery together with and on behalf of the hematology community.

For more information and resources on blood cancers, we encourage you to visit Lymphoma Research Foundation or the Leukemia & Lymphoma Society. To locate a clinical trial underway in blood cancers and other disease areas, visit our Cancer Study Locator website where you can match you or your loved one’s profile to available trials.